Showing 511-520 of 7860 results for "".
Increased APS Risk for Psoriasis Patients, Plus More
https://practicaldermatology.com/series/dermwire-tv/increased-aps-risk-for-psoriasis-patients-plus-more/39299/This episode highlights research showing increased risk for anti-phospholipid syndrome (APS) in patients with psoriatic disease, as well as research showing increased risks for tuberculosis in patients treated with immunosuppressants. The episode also features a clip from an in-depth discussion arouDWTV Extra: Vitiligo Ingenuity Award
https://practicaldermatology.com/programs/practical-dermatology/dwtv-extra-vitiligo-ingenuity-award/37869/Hannah Metheny, a student at the University of Miami Miller School of Medicine, discusses winning an Incyte Ingenuity Award in Vitiligo for the "Barriers and Facilitators to Psychosocial Support as an Integral Aspect of Vitiligo Patient Comprehensive Care" project.DermwireTV: DermaRite Issues Recall for Several Hand Soaps
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-dermarite-issues-recall-for-several-hand-soaps/37113/In this episode, new research shows switching between interclass biologics may be safe and effective for psoriasis patients; DermaRite recalls 4 skin care products over contamination concerns; and awareness grows for generalized pustular psoriasis through a new global awareness campaign.FDA Grants Interchangeability to HADLIMA
https://practicaldermatology.com/series/dermwire-tv/fda-grants-interchangeability-to-hadlima/35962/In this week's DermwireTV, the FDA grants full interchangeability to HADLIMA; new research shows the impact of UV exposure on global skin cancer cases; and coverage from Music City SCALE addresses barriers to patient access to new therapies.Nail Disease and JAK Inhibitor Safety
https://reachmd.com/programs/practical-dermatology/nail-disease-and-jak-inhibitor-safety/35897/Brad Glick, DO, talks about the basics of nail anatomy, physiology, disease presentation, and treatments, as well as the safety of JAK inhibitors, at Music City SCALE 2025.AAD Leaders Discuss New Goals and Initiatives
https://practicaldermatology.com/series/dermwire-tv/aad-leaders-discuss-new-goals-and-initiatives/33154/In this week's DermwireTV, leaders of the American Academy of Dermatology (AAD) discuss the key issues facing the specialty; a new study examines nicotinamide exposure and the risk of major adverse cardiovascular events; and in our C-Suite Chats segment, we hear from an Executive Director at TakeImproving the After-Sun Treatment Market
https://practicaldermatology.com/series/c-suite-chats/improving-after-sun-treatment-market/29805/Ed Esquenazi, PhD, Founder and CEO of health and performance company, Terns, discusses the after-sun treatment market and two new products designed to combat inflammation and aging after exposure to the sun.Talking to Patients About Starting a JAK Inhibitor in Atopic Dermatitis
https://practicaldermatology.com/series/pa-perspectives/talking-patients-about-starting-jak-inhibitor-atopic-dermatitis/26919/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, discusses the importance of offering patients quick access to medication, and tips on how to best discuss safety.Get Ready for JAK Inhibitors
https://practicaldermatology.com/topics/psoriasis/get-ready-for-jak-inhibitors/19928/JAK inhibitors are going to change the way we think about refractory disease, says Brett King, MD. He addresses the significant increase in study of these agents and the many potential uses for refractory diseases like alopecia, atopic dermatitis, vitiligo, psoriasis, and more.Itching for Answers: Understanding and Treating Pruritus
https://practicaldermatology.com/topics/general-topics/itching-for-answers-understanding-and-treating-pruritus/18493/Since childhood, when he was affected by eczema and associated pruritus, Ethan Lerner, MD, PhD has been fascinated by itch, its causes, and its potential treatments. In this edition of Benchside Dispatches, he offers a fresh look at the latest research on pruritus and the challenges facing scientist